text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 127-07-1 | Product Number: H0310

Hydroxyurea


Purity: >97.0%(N)
Synonyms:
Documents:
5G
£12.00
1   ≥20 
25G
£35.00
1   ≥20 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number H0310
Purity / Analysis Method >97.0%(N)
Molecular Formula / Molecular Weight CH__4N__2O__2 = 76.06  
Physical State (20 deg.C) Solid
Store Under Inert Gas Store under inert gas
Condition to Avoid Hygroscopic
CAS RN 127-07-1
Reaxys Registry Number 1741548
PubChem Substance ID 87570732
SDBS (AIST Spectral DB) 3920
Merck Index (14) 4848
MDL Number

MFCD00007943

Specifications
Appearance White to Almost white powder to crystal
Purity(with Total Nitrogen) min. 97.0 %
Properties (reference)
Melting Point 140 °C
GHS
Pictogram Pictogram
Signal Word Danger
Hazard Statements H361 : Suspected of damaging fertility or the unborn child.
H340 : May cause genetic defects.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P202 : Do not handle until all safety precautions have been read and understood.
P201 : Obtain special instructions before use.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P405 : Store locked up.
Related Laws:
EC Number 204-821-7
RTECS# YT4900000
Transport Information:
UN Number UN2811
Class 6.1
Packing Group III
HS Number 2928009090
Application
Hydroxyurea (or hydroxycarbamide): A Ribonucleotide Reductase Inhibitor

Hydroxyurea (or hydroxycarbamide), a hydroxylated molecule of urea [U0077][U0073], is classified as an antitumor antimetabolite. Hydroxyurea inhibits deoxynucleotide and DNA synthesis by blocking the cellular enzyme ribonucleotide reductase, which is responsible for producing the deoxynucleotides required for DNA synthesis and repair, producing cell death in S phase (the phase of DNA synthesis). Recently, two effects of hydroxyurea have been reported: hydroxyurea increases the level of fetal hemoglobin, leading to a reduction in the incidence of vaso-occlusive crises in sickle cell anemia, and hydroxyurea inhibits human immunodeficiency virus-type 1 (HIV-1) DNA synthesis. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Documents
Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents